BioXcel Therapeutics (NASDAQ:BTAI) Rating Reiterated by HC Wainwright
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 269.00% from the stock’s current price. BTAI has […]
More Stories
Tenet Healthcare (NYSE:THC) Price Target Raised to $150.00 at UBS Group
Tenet Healthcare (NYSE:THC – Free Report) had its price objective increased by UBS Group from $137.00 to $150.00 in a...
JPMorgan Chase & Co. Trims Molson Coors Beverage (NYSE:TAP) Target Price to $60.00
Molson Coors Beverage (NYSE:TAP – Free Report) had its price target reduced by JPMorgan Chase & Co. from $66.00 to...
Piper Sandler Trims Sysco (NYSE:SYY) Target Price to $79.00
Sysco (NYSE:SYY – Free Report) had its target price lowered by Piper Sandler from $83.00 to $79.00 in a research...
Republic Services (NYSE:RSG) Price Target Raised to $204.00
Republic Services (NYSE:RSG – Free Report) had its price target upped by Oppenheimer from $202.00 to $204.00 in a research...
JPMorgan Chase & Co. Raises Truist Financial (NYSE:TFC) Price Target to $40.50
Truist Financial (NYSE:TFC – Free Report) had its target price hoisted by JPMorgan Chase & Co. from $39.50 to $40.50...
James River Group (NASDAQ:JRVR) & The Seibels Bruce Group (OTCMKTS:SBBG) Head-To-Head Survey
The Seibels Bruce Group (OTCMKTS:SBBG – Get Free Report) and James River Group (NASDAQ:JRVR – Get Free Report) are both...